Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmania amazonensis promastigotes

Rebello, Karina M.; Andrade Neto, Valter V.; Zuma, Aline A.; Motta, Maria Cristina M.; Gomes, Claudia Regina B.; Souza, Marcus Vinícius N. de; Atella, Geórgia C.; Branquinha, Marta H.; Santos, André L. S.; Santos, Eduardo Caio Torres; d`Avila-Levy,&; 160;Claudia&; 160;M..
Artículo en Inglés | ARCA | ID: arc-29450

Documentos relacionados

  1. Multiple Molecular Dynamics Simulations of the Inhibitor GRL-02031 Complex with Wild Type and Mutant HIV-1 Protease Reveal the Binding and Drug-Resistance Mechanism.
  2. Peptide Amphiphilic-Based Supramolecular Structures with Anti-HIV-1 Activity.
  3. Exploring the energetic basis of binding of currently used drugs against HIV-1 subtype CRF01_AE protease via molecular dynamics simulations.
  4. Machine learning-guided design of potent darunavir analogs targeting HIV-1 proteases: A computational approach for antiretroviral drug discovery.
  5. The loud minority: Transcriptionally active HIV-1-infected cells survive, proliferate, and persist.
  6. Revisiting the recombinant history of HIV-1 group M with dynamic network community detection.
  7. Comparative Analysis of Differential Cellular Transcriptome and Proteome Regulation by HIV-1 and HIV-2 Pseudovirions in the Early Phase of Infection.
  8. NMR study of xenotropic murine leukemia virus-related virus protease in a complex with amprenavir.
  9. Leishmania (Sauroleishmania) tarentolae versus pathogenic species: comparative evaluation of protease activity, glycoconjugates, resistance to complement and metabolome composition.
  10. HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.